UCLA
6 SlideShares 3 Abonné 1 Suivi
Personal Information
Entreprise/Lieu de travail
San Francisco Bay Area, California United States
Secteur d’activité
Education
Site Web
www.MiraKind.org
À propos
I am an oncologist and molecular biologist, who has dedicated my life to improving the care of cancer patients. I have worked to apply novel and progressive scientific findings to critical issues in cancer care. Through these efforts I have started a genetics company, MiraDx, and a non-profit, MiraKind.
Coordonnées
Mots-clés
kras-variant inherited gene mutation inherited cancer risk miradx microrna triple negative breast cancer prevention cancer research biomarker infertility endometriosis genetic marker joanne weidhaas germline cancer studies breast cancer lung cancer mirakind hboc weidhaas weidhaas jb double primary breast and ovarian cancer ovarian cancer gene mutation brca1 cancer germline variant endometrial cancer yale school of medicine platinum resistance yale university
Tout plus

Présentations

(2)

MiraKind 6 and 25 percent banner

il y a 9 ans • 125 Vues

MiraKind Breast Cancer Awareness

il y a 9 ans • 142 Vues

Documents

(4)
Tout voir

The KRAS-Variant Is Associated with Risk of Developing Double Primary Breast and Ovarian Cancer

il y a 9 ans • 407 Vues

A KRAS-variant is a Biomarker of Poor Outcome, Platinum Chemotherapy Resistance and a Potential Target for Therapy in Ovarian Cancer

il y a 9 ans • 764 Vues

The KRAS-Variant and miRNA Expression in RTOG Endometrial Cancer Clinical Trials 9708 and 9905

il y a 9 ans • 434 Vues

A 3′-untranslated region KRAS variant and triple-negative breast cancer: a case-control and genetic analysis

il y a 9 ans • 439 Vues
Personal Information
Entreprise/Lieu de travail
San Francisco Bay Area, California United States
Secteur d’activité
Education
Site Web
www.MiraKind.org
À propos
I am an oncologist and molecular biologist, who has dedicated my life to improving the care of cancer patients. I have worked to apply novel and progressive scientific findings to critical issues in cancer care. Through these efforts I have started a genetics company, MiraDx, and a non-profit, MiraKind.
Mots-clés
kras-variant inherited gene mutation inherited cancer risk miradx microrna triple negative breast cancer prevention cancer research biomarker infertility endometriosis genetic marker joanne weidhaas germline cancer studies breast cancer lung cancer mirakind hboc weidhaas weidhaas jb double primary breast and ovarian cancer ovarian cancer gene mutation brca1 cancer germline variant endometrial cancer yale school of medicine platinum resistance yale university
Tout plus